| 英文名称 |
中文名称 |
CAS号 |
操作 |
| Fluvastatin sodium |
氟伐他汀钠 |
93957-55-2 |
详细
|
| IPA-3 |
IPA-3 |
42521-82-4 |
详细
|
| KX2-391 |
5-[4-[2-(4-吗啉基)乙氧基]苯基]-N-(苯基甲基)-2-吡啶乙酰胺 |
897016-82-9 |
详细
|
| T-5224 |
T-5224 |
530141-72-1 |
详细
|
| ATN-161 |
262438-43-7 |
262438-43-7 |
详细
|
| Crenolanib (CP-868596) |
1-[2-[5-(3-甲基氧杂环丁烷-3-基甲氧基)苯并咪唑-1-基]喹啉-8-基]哌啶-4-基]胺 |
670220-88-9 |
详细
|
| PRT062607 Hydrochloride |
PRT062607 (HYDROCHLORIDE) |
1370261-97-4 |
详细
|
| AZD1208 |
AZD1208 |
1204144-28-4 |
详细
|
| UNC1999 |
UNC1999 |
1431612-23-5 |
详细
|
| PTC-209 |
PTC-209 |
315704-66-6 |
详细
|
| KIRA6 |
CS-2625 |
1589527-65-0 |
详细
|
| UK-5099 |
UK 5099 |
56396-35-1 |
详细
|
| EHT 1864 |
EHT 1864 |
754240-09-0 |
详细
|
| Fatostatin A |
FATOSTATIN |
298197-04-3 |
详细
|
| 6-fluoro-N-(4-fluorobenzyl)quinazolin-4-aMine |
Spautin-1抑制剂 |
1262888-28-7 |
详细
|
| Tanzisertib |
TANZISERTIB |
899805-25-5 |
详细
|
| TMP195 |
TMP195游离态 |
1314891-22-9 |
详细
|
| K02288 |
K02288 |
1431985-92-0 |
详细
|
| TIC10 (ONC201) |
ONC201 |
1616632-77-9 |
详细
|
| NMS-P937 (NMS1286937) |
4,5-二氢-1-(2-羟基乙基)-8-[[5-(4-甲基-1-哌嗪基)-2-(三氟甲氧基)苯基]氨基]-1H-吡唑并[4,3-H]喹唑啉-3-甲酰胺 |
1034616-18-6 |
详细
|
| BMS-202 |
PD1-PDL1抑制剂2 |
1675203-84-5 |
详细
|
| Clopidogrel hydrogen sulfate |
硫酸氯吡格雷 |
120202-66-6 |
详细
|
| 4-Benzyl-2-(naphthalen-1-yl)-[1,2,4]thiadiazolidine-3,5-dione |
4-苄基-2-(萘-1-基)-[1,2,4]噻二唑烷-3,5-二酮 |
865854-05-3 |
详细
|
| LMK-235 |
N-[[6-(羟基氨基)-6-氧代己基]氧基]-3,5-二甲基-苯甲酰胺 |
1418033-25-6 |
详细
|
| Poziotinib (HM781-36B) |
波齐替尼 |
1092364-38-9 |
详细
|
| BAY 87-2243 |
BAY87-2243 |
1227158-85-1 |
详细
|
| SP2509 |
无中文名称 |
1423715-09-6 |
详细
|
| PKM2-IN-1 |
COMPOUND 3K |
94164-88-2 |
详细
|
| (3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-Trimethyldecahydro-3H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-ol |
双氢青蒿素 |
71939-50-9 |
详细
|
| DC661 |
DC661 |
1872387-43-3 |
详细
|
| Lonafarnib |
洛那法尼 |
193275-84-2 |
详细
|
| 3,5-Dichloro-2-hydroxy-N-(4-methoxy-[1,1'-biphenyl]-3-yl)benzenesulfonamide |
BMS303141 |
943962-47-8 |
详细
|
| PND-1186 |
PND1186 |
1061353-68-1 |
详细
|
| SKL 2001 |
SKL2001 |
909089-13-0 |
详细
|
| Salubrinal |
SALUBRINAL |
405060-95-9 |
详细
|
| E-64 |
N-(反式-环氧丁二酰基)-L-亮氨酸-4-胍基丁基酰胺 |
66701-25-5 |
详细
|
| CFDA-SE |
5(6)-羧基二乙酸荧光素琥珀酰亚胺酯 |
150347-59-4 |
详细
|
| Rimonabant |
利莫那班 |
168273-06-1 |
详细
|
| GW6471 |
GW 6471 |
880635-03-0 |
详细
|
| Cryptotanshinone |
隐丹参酮 |
35825-57-1 |
详细
|
| PF-573228 |
6-[(4-((3-(甲磺酰基)苄基)氨基)-5-三氟甲基嘧啶-2-基)氨基]-3,4-二氢-1H-喹啉-2-酮 |
869288-64-2 |
详细
|
| 5-[2-[4-[2-(Dimethylamino)ethoxy]phenyl]-5-(4-pyridinyl)-1H-imidazol-4-yl]-2,3-dihydro-1H-inden-1-one oxime |
5-[2-[4-[2-(二甲基氨基)乙氧基]苯基]-5-(4-吡啶基)-1H-咪唑-4-基]-2,3-二氢-1-茚酮肟 |
405554-55-4 |
详细
|
| Mocetinostat(MGCD0103) |
N-(2-氨基苯基)-4-([[4-(吡啶-3-基)嘧啶-2-基]氨基]甲基)苯甲酰胺 |
726169-73-9 |
详细
|
| Cilengitide TFA |
EMD 121974; NSC 707544 |
199807-35-7 |
详细
|
| NVP-TNKS656 |
NVP-TNKS656 |
1419949-20-4 |
详细
|
| ODM-201 |
达洛鲁胺 |
1297538-32-9 |
详细
|
| OICR-9429 |
N-(4-(4-甲基哌嗪-1-基)-3'-(吗啉代甲基)-[1,1'-联苯]-3-基)-6-氧代-4-(三氟甲基)-1,6-二氢吡啶-3-甲酰胺 |
1801787-56-3 |
详细
|
| PF-543 hydrochloride |
PF-543 |
1706522-79-3 |
详细
|
| dBET6 |
1950634-92-0 |
1950634-92-0 |
详细
|
| RU.521 |
RU320521 |
2262452-06-0 |
详细
|
| Calpeptin |
CALPEPTIN |
117591-20-5 |
详细
|
| AG490 |
酪氨酸磷酸化抑制剂AG 490 |
133550-30-8 |
详细
|
| GSK2879552 dihydrochloride |
GSK2879552 |
1902123-72-1 |
详细
|
| Rigosertib (ON-01910) |
N-[2-甲氧基-5-[[[2-(2,4,6-三甲氧基苯基)乙烯基]磺酰]甲基]苯基]甘氨酸钠盐 |
1225497-78-8 |
详细
|
| Refametinib |
瑞法替尼 |
923032-37-5 |
详细
|
| BMS 777607 |
N-[4-[(2-氨基-3-氯吡啶-4-基)氧基]-3-氟苯基]-4-乙氧基-1-(4-氟苯基)-2-氧代-1,2-二氢吡啶-3-甲酰胺 |
1025720-94-8 |
详细
|
| PCI-34051 |
N-羟基-1-(4-甲氧基苄基)-1H-吲哚-6-甲酰胺 |
950762-95-5 |
详细
|
| JIB-04 |
5-氯-2(1H)-吡啶酮 (2E)-(苯基-2-吡啶基亚甲基)腙 |
199596-05-9 |
详细
|
| SGC-CBP30 |
SGC-CBP30 |
1613695-14-9 |
详细
|
| Ac-CoA Synthase Inhibitor1 |
1-(2,3-二(噻吩-2-基)喹啉-6-基)-3-(2-甲氧基乙基)脲 |
508186-14-9 |
详细
|
| GW3965 HCl |
2-[3-[3-[[2-氯-3-(三氟甲基)苄基](2,2-二苯基乙基)氨基]丙氧基]苯基]乙酸盐酸盐 |
405911-17-3 |
详细
|
| STO-609 |
STO-609 |
52029-86-4 |
详细
|
| GSK2334470 |
GSK2334470 |
1227911-45-6 |
详细
|
| ML-265 |
ML-265 |
1221186-53-3 |
详细
|
| Importazole |
CS-2426 |
662163-81-7 |
详细
|
| GSK2656157 |
GSK2656157 |
1337532-29-2 |
详细
|
| OSS_128167 |
OSS-128167 |
887686-02-4 |
详细
|
| SCH900776 |
6-溴-3-(1-甲基-1H-吡唑-4-基)-5-(3R)-3-哌啶基吡唑并[1,5-A]嘧啶-7-胺 |
891494-63-6 |
详细
|
| CAY10683 (SantacruzaMate A) |
HDAC抑制剂 |
1477949-42-0 |
详细
|
| BAY-876 |
BAY-876 |
1799753-84-6 |
详细
|
| AMG900 |
AMG 900 |
945595-80-2 |
详细
|
| Degrasyn |
WP1130 |
856243-80-6 |
详细
|
| Pacritinib |
帕克替尼 |
937272-79-2 |
详细
|
| NMS-873 |
NMS873 |
1418013-75-8 |
详细
|
| Mirin |
(5Z)-2-氨基-5-[(4-羟基苯基)亚甲基]-4(5H)-噻唑酮 |
1198097-97-0 |
详细
|
| SBI-0206965 |
SBI0206965; SBI-0206965; SBI 0206965. |
1884220-36-3 |
详细
|
| THZ531 |
THZ531 |
1702809-17-3 |
详细
|
| NCT-503 |
NCT503 |
1916571-90-8 |
详细
|
| AZD5153 6-Hydroxy-2-naphthoic acid |
AZD5153结晶体(API形式) |
1869912-40-2 |
详细
|
| KN-62 |
1-[N,O-二(5-异喹啉磺酰基)-N-甲基-L-型酪氨酸]-4-苯基哌嗪 |
127191-97-3 |
详细
|
| FB23-2 |
FB23-2 |
2243736-45-8 |
详细
|
| NU7026 |
2-(4-吗啉基)-4H-萘并[1,2-B]吡喃-4-酮 |
154447-35-5 |
详细
|
| GW 4064 |
3-(2,6-二氯苯基)-4-(3'-羧基-2-氯二苯乙烯-4-基)氧甲基-5-异丙基异恶唑 |
278779-30-9 |
详细
|
| TED-347 |
化合物TED-347 |
2378626-29-8 |
详细
|
| Daptomycin |
达托霉素 |
103060-53-3 |
详细
|
| LW6 |
LW 6 |
934593-90-5 |
详细
|
| Bafetinib |
巴氟替尼 |
859212-16-1 |
详细
|
| I-BET151 |
7-(3,5-二甲基异噁唑-4-基)-8-甲氧基-1-((R)-1-(吡啶-2-基)乙基)-1H-咪唑并[4,5-C]喹啉-2(3H)-酮 |
1300031-49-5 |
详细
|
| CK 1827452 |
4-[[2-氟-3-[N'-(6-甲基吡啶-3-基)脲基]苯基]甲基]哌嗪-1-羧酸甲酯 |
873697-71-3 |
详细
|
| Pioglitazone |
匹格列酮 |
111025-46-8 |
详细
|
| 10074-G5 |
N-2-联苯基-7-硝基-2,1,3-苯并恶二唑-4-胺 |
413611-93-5 |
详细
|
| ARN509 |
阿帕鲁胺 |
956104-40-8 |
详细
|
| EPZ004777 |
EPZ004777 |
1338466-77-5 |
详细
|
| SAR 131675 |
SAR131675 |
1433953-83-3 |
详细
|
| GS-9973 |
GS-9973 |
1229208-44-9 |
详细
|
| Vps34-IN-1 |
VPS34-IN1 |
1383716-33-3 |
详细
|
| Paxalisib (GDC-0084) |
GDC-0084 |
1382979-44-3 |
详细
|
| Siremadlin |
NVP-HDM201 |
1448867-41-1 |
详细
|
| ULK-101 |
2-Thiophenecarboxamide, N-[(1S)-1-cyclopropyl-2,2,2-trifluoroethyl]-4-[6-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]- |
2443816-45-1 |
详细
|
| Elacridar |
依克立达 |
143664-11-3 |
详细
|